Mark Belletrutti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mark Belletrutti has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- David B. Nicholas
Faculty of Social Work, University of Calgary, Calgary, AB T2N 1N4, Canada
3 shared publications Adam Rapoport
The Hospital for Sick Children , Toronto (Ontario) Canada
2 shared publicationsAisha Bruce
Département de pédiatrie, Université de l’Alberta , Edmonton (Alberta) Canada
2 shared publications- Anthony Kam Chuen Chan
McMaster University, Hamilton, Canada
2 shared publications Emma Cullen
Faculté de travail social, Université de Calgary , Calgary (Alberta) Canada
2 shared publicationsGina Dimitropoulos
Faculté de travail social, Université de Calgary , Calgary (Alberta) Canada
2 shared publications
Latest Publications
- Open Access
- 8 September 2022
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 27 (Supplement) , S115-S122
Les effets de la pandémie de COVID-19 sur la santé mentale des enfants atteints de problèmes de santé physique ou d’incapacités, des familles et des professionnels de la santé
Résumé: Objectifs: La pandémie de COVID-19 a influé sur la santé mentale de la population. Les familles des enfants qui ont des vulnérabilités en matière de santé ont été démesurément touchées par les politiques liées à la pandémie et les perturbations aux services, car elles s’appuient beaucoup sur le système de soins de santé et de services sociaux. Les chercheurs ont établi les répercussions de la pandémie de COVID-19 sur les enfants ayant des vulnérabilités en matière de santé physique et des incapacités, les familles et les professionnels de la santé. Méthodologie: Des enfants ayant diverses vulnérabilités en matière de santé (transplantation cardiaque, affections respiratoires, anémie falciforme, trouble du spectre de l’autisme, troubles de santé mentale et approche de la fin de vie en raison d’une série de causes sous-jacentes), leurs parents et leurs professionnels de la santé ont participé à des entrevues semi-structurées. Les chercheurs ont utilisé des méthodes d’analyse qualitative et en ont extrait les thèmes liés aux effets et les recommandations en vue d’améliorer la pratique. Résultats: Au total, 262 participants (30 enfants, 76 parents, 156 professionnels de la santé) ont été interviewés. Les enfants ont décrit leur solitude et leur isolement, les parents, leur épuisement, et les professionnels de la santé, la pression ressentie et un sentiment de détresse morale. Les thèmes reflétaient les effets de la pandémie sur la santé mentale des enfants, des familles et des professionnels de la santé, de même que les ressources insuffisantes pour soutenir la santé mentale, les influences organisationnelles et politiques qui ont façonné la prestation des services et les recommandations pour améliorer la prestation de ces services. Conclusion: Les restrictions sanitaires imposées par la pandémie et les modifications aux soins ont eu de profondes répercussions sur la santé mentale des enfants qui ont des vulnérabilités en matière de santé, les familles et les professionnels de la santé. Les recommandations incluent la rédaction et l’adoption d’information ciblée sur la pandémie et la mise en œuvre de services de soutien en santé mentale. Ces résultats amplifient la nécessité de renforcer les capacités, y compris des stratégies proactives et la planification de mesures d’atténuation du risque dans l’éventualité d’une future pandémie.
- 8 September 2022
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 27 (Supplement) , S115-S122
Open AccessLes effets de la pandémie de COVID-19 sur la santé mentale des enfants atteints de problèmes de santé physique ou d’incapacités, des familles et des professionnels de la santé
Résumé: Objectifs: La pandémie de COVID-19 a influé sur la santé mentale de la population. Les familles des enfants qui ont des vulnérabilités en matière de santé ont été démesurément touchées par les politiques liées à la pandémie et les perturbations aux services, car elles s’appuient beaucoup sur le système de soins de santé et de services sociaux. Les chercheurs ont établi les répercussions de la pandémie de COVID-19 sur les enfants ayant des vulnérabilités en matière de santé physique et des incapacités, les familles et les professionnels de la santé. Méthodologie: Des enfants ayant diverses vulnérabilités en matière de santé (transplantation cardiaque, affections respiratoires, anémie falciforme, trouble du spectre de l’autisme, troubles de santé mentale et approche de la fin de vie en raison d’une série de causes sous-jacentes), leurs parents et leurs professionnels de la santé ont participé à des entrevues semi-structurées. Les chercheurs ont utilisé des méthodes d’analyse qualitative et en ont extrait les thèmes liés aux effets et les recommandations en vue d’améliorer la pratique. Résultats: Au total, 262 participants (30 enfants, 76 parents, 156 professionnels de la santé) ont été interviewés. Les enfants ont décrit leur solitude et leur isolement, les parents, leur épuisement, et les professionnels de la santé, la pression ressentie et un sentiment de détresse morale. Les thèmes reflétaient les effets de la pandémie sur la santé mentale des enfants, des familles et des professionnels de la santé, de même que les ressources insuffisantes pour soutenir la santé mentale, les influences organisationnelles et politiques qui ont façonné la prestation des services et les recommandations pour améliorer la prestation de ces services. Conclusion: Les restrictions sanitaires imposées par la pandémie et les modifications aux soins ont eu de profondes répercussions sur la santé mentale des enfants qui ont des vulnérabilités en matière de santé, les familles et les professionnels de la santé. Les recommandations incluent la rédaction et l’adoption d’information ciblée sur la pandémie et la mise en œuvre de services de soutien en santé mentale. Ces résultats amplifient la nécessité de renforcer les capacités, y compris des stratégies proactives et la planification de mesures d’atténuation du risque dans l’éventualité d’une future pandémie.
- Open Access
- 9 May 2022
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 27 (Supplement) , S33-S39
Mental health impacts of the COVID-19 pandemic on children with underlying health and disability issues, and their families and health care providers
Objectives: The COVID-19 pandemic has impacted mental health at a population level. Families of children with health vulnerabilities have been disproportionately affected by pandemic-related policies and service disruptions as they substantially rely on the health and social care system. We elicited the impact of the COVID-19 pandemic on children with health and disability-related vulnerabilities, their families, and their health care providers (HCPs). Methods: Children with diverse health vulnerabilities (cardiac transplantation, respiratory conditions, sickle cell disease, autism spectrum disorder, mental health issues, and nearing the end of life due to a range of underlying causes), as well as their parents and HCPs, participated in semi-structured interviews. Data were analyzed using qualitative content analysis in determining themes related to impact and recommendations for practice improvement. Results: A total of 262 participants (30 children, 76 parents, 156 HCPs) were interviewed. Children described loneliness and isolation; parents described feeling burnt out; and HCPs described strain and a sense of moral distress. Themes reflected mental health impacts on children, families, and HCPs, with insufficient resources to support mental health; organizational and policy influences that shaped service delivery; and recommendations to enhance service delivery. Conclusion: Children with health vulnerabilities, their families and HCPs incurred profound mental health impacts due to pandemic-imposed public health restrictions and care shifts. Recommendations include the development and application of targeted pandemic information and mental health supports. These findings amplify the need for capacity building, including proactive strategies and mitigative planning in the event of a future pandemic.
- 9 May 2022
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 27 (Supplement) , S33-S39
Open AccessMental health impacts of the COVID-19 pandemic on children with underlying health and disability issues, and their families and health care providers
Objectives: The COVID-19 pandemic has impacted mental health at a population level. Families of children with health vulnerabilities have been disproportionately affected by pandemic-related policies and service disruptions as they substantially rely on the health and social care system. We elicited the impact of the COVID-19 pandemic on children with health and disability-related vulnerabilities, their families, and their health care providers (HCPs). Methods: Children with diverse health vulnerabilities (cardiac transplantation, respiratory conditions, sickle cell disease, autism spectrum disorder, mental health issues, and nearing the end of life due to a range of underlying causes), as well as their parents and HCPs, participated in semi-structured interviews. Data were analyzed using qualitative content analysis in determining themes related to impact and recommendations for practice improvement. Results: A total of 262 participants (30 children, 76 parents, 156 HCPs) were interviewed. Children described loneliness and isolation; parents described feeling burnt out; and HCPs described strain and a sense of moral distress. Themes reflected mental health impacts on children, families, and HCPs, with insufficient resources to support mental health; organizational and policy influences that shaped service delivery; and recommendations to enhance service delivery. Conclusion: Children with health vulnerabilities, their families and HCPs incurred profound mental health impacts due to pandemic-imposed public health restrictions and care shifts. Recommendations include the development and application of targeted pandemic information and mental health supports. These findings amplify the need for capacity building, including proactive strategies and mitigative planning in the event of a future pandemic.
- Open Access
- 7 May 2021
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (4) , e12519
Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
- 7 May 2021
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 5 (4) , e12519
Open AccessMeasuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
- Open Access
- 2 September 2020
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 26 (5) , 274-275
The curious case of the bleeding twins: Neonatal bleeding secondary to acetylsalicylic acid prescribed for preeclampsia prevention
Preeclampsia is a major cause of obstetric and perinatal morbidity and mortality ( 1). Guidelines recommend acetylsalicylic acid (ASA) prophylaxis in pregnant women with certain risk factors to mitigate maternal vascular dysfunction and prevent consequences of preeclampsia ( 1–3). According to Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines, low-dose ASA (75 mg/day to 162 mg/day) should be prescribed for high-risk patients. Risk factors include advanced maternal age, personal or family history of preeclampsia, pre-existing medical conditions, obesity, and multiple pregnancy. Therapy should be initiated before 16 weeks’ gestation and continued until delivery...
- 2 September 2020
- Published by Oxford University Press (OUP) in Paediatrics & Child Health
- Vol. 26 (5) , 274-275
Open AccessThe curious case of the bleeding twins: Neonatal bleeding secondary to acetylsalicylic acid prescribed for preeclampsia prevention
Preeclampsia is a major cause of obstetric and perinatal morbidity and mortality ( 1). Guidelines recommend acetylsalicylic acid (ASA) prophylaxis in pregnant women with certain risk factors to mitigate maternal vascular dysfunction and prevent consequences of preeclampsia ( 1–3). According to Society of Obstetricians and Gynaecologists of Canada (SOGC) guidelines, low-dose ASA (75 mg/day to 162 mg/day) should be prescribed for high-risk patients. Risk factors include advanced maternal age, personal or family history of preeclampsia, pre-existing medical conditions, obesity, and multiple pregnancy. Therapy should be initiated before 16 weeks’ gestation and continued until delivery...
- 2 January 2020
- Published by Taylor & Francis in Journal of Social Work in End-of-Life & Palliative Care
- Vol. 16 (1) , 42-56
Engaging Fathers in Pediatric Palliative Care Research
Fathers are under-represented in pediatric palliative care research despite frequently playing a key role in the lives of their children. The purpose of this study was to identify factors that affected paternal study invitation and participation. A secondary mixed-methods evaluation design guided examination of interview and focus group data as well as field notes from a qualitative study that examined the experiences and support needs of fathers of children with a life-limiting illness. Facilitators of paternal participation in the study consisted of: fathers’ desire to gain from study participation either for themselves or others, perception of the study’s importance, sense of appreciation for the study’s focus on fathers and an established relationship with recruiting health care providers. Barriers to study participation included: recruiting health care providers’ appraisal of fathers’ lack of well-being, bereaved fathers’ self-reported poor coping and the inability to locate and contact fathers, particularly after a child’s death. Strategies for improving the engagement of fathers into research entailed: educating recruitment personnel, designing “father-focused” studies, communicating the value of the research to recruitment personnel and potential participants, and ensuring that child health records are accurate and include fathers’ contact information.
- 2 January 2020
- Published by Taylor & Francis in Journal of Social Work in End-of-Life & Palliative Care
- Vol. 16 (1) , 42-56
Engaging Fathers in Pediatric Palliative Care Research
Fathers are under-represented in pediatric palliative care research despite frequently playing a key role in the lives of their children. The purpose of this study was to identify factors that affected paternal study invitation and participation. A secondary mixed-methods evaluation design guided examination of interview and focus group data as well as field notes from a qualitative study that examined the experiences and support needs of fathers of children with a life-limiting illness. Facilitators of paternal participation in the study consisted of: fathers’ desire to gain from study participation either for themselves or others, perception of the study’s importance, sense of appreciation for the study’s focus on fathers and an established relationship with recruiting health care providers. Barriers to study participation included: recruiting health care providers’ appraisal of fathers’ lack of well-being, bereaved fathers’ self-reported poor coping and the inability to locate and contact fathers, particularly after a child’s death. Strategies for improving the engagement of fathers into research entailed: educating recruitment personnel, designing “father-focused” studies, communicating the value of the research to recruitment personnel and potential participants, and ensuring that child health records are accurate and include fathers’ contact information.
- 8 November 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Severe haemophilia A in a neonate presenting as haemopneumothorax after tracheo-oesophageal fistula-oesophageal atresia repair
A male infant with oesophageal atresia and distal tracheo-oesophageal fistula (TEF type C) underwent right thoracotomy and transpleural repair of TEF on day 4 of life. He did not have a family history of coagulation disorders. A preoperative finding of prolonged partial thromboplastin time (PTT)>200 s was overlooked, and he went to surgery. There were no concerns with haemostasis prior to and even during the operation. The prolonged PTT was treated with one 10 mL/kg dose of fresh frozen plasma in the immediate postoperative period. On the fourth postoperative day, the infant developed a right haemopneumothorax, requiring fresh frozen plasma and packed cell transfusions. He was subsequently diagnosed with severe haemophilia A due to intron 22 inversion in the factor VIII gene, with factor VIII level <0.01 IU/mL.
- 8 November 2018
- Published by BMJ in BMJ Case Reports
- Vol. 2018
Severe haemophilia A in a neonate presenting as haemopneumothorax after tracheo-oesophageal fistula-oesophageal atresia repair
A male infant with oesophageal atresia and distal tracheo-oesophageal fistula (TEF type C) underwent right thoracotomy and transpleural repair of TEF on day 4 of life. He did not have a family history of coagulation disorders. A preoperative finding of prolonged partial thromboplastin time (PTT)>200 s was overlooked, and he went to surgery. There were no concerns with haemostasis prior to and even during the operation. The prolonged PTT was treated with one 10 mL/kg dose of fresh frozen plasma in the immediate postoperative period. On the fourth postoperative day, the infant developed a right haemopneumothorax, requiring fresh frozen plasma and packed cell transfusions. He was subsequently diagnosed with severe haemophilia A due to intron 22 inversion in the factor VIII gene, with factor VIII level <0.01 IU/mL.
- 22 October 2015
- Published by BMJ in BMJ Case Reports
- Vol. 2015
HbM methaemoglobinaemia as a rare case of early neonatal benign cyanosis
Early neonatal central cyanosis that is unrelated to cardiopulmonary causes, alerts clinicians to possibility of methaemoglobinaemia. Congenital methaemoglobinaemia due to haemoglobin M is an autosomal dominant disorder characterised by lifelong cyanosis. We report a case presentation and review of diagnostic pitfalls of a newborn who presented with central cyanosis; investigations revealed a low methaemoglobin reductase (2.2 IU/g Hb), with normal maternal levels (9.1 IU/g Hb). Therefore, haemoglobinopathy investigations were completed on the mother and her baby, which showed an α-globin variant in both. The maternal α2 globin gene sequencing showed heterozygosity for haemoglobin M Boston (α58 His→Tyr).
- 22 October 2015
- Published by BMJ in BMJ Case Reports
- Vol. 2015
HbM methaemoglobinaemia as a rare case of early neonatal benign cyanosis
Early neonatal central cyanosis that is unrelated to cardiopulmonary causes, alerts clinicians to possibility of methaemoglobinaemia. Congenital methaemoglobinaemia due to haemoglobin M is an autosomal dominant disorder characterised by lifelong cyanosis. We report a case presentation and review of diagnostic pitfalls of a newborn who presented with central cyanosis; investigations revealed a low methaemoglobin reductase (2.2 IU/g Hb), with normal maternal levels (9.1 IU/g Hb). Therefore, haemoglobinopathy investigations were completed on the mother and her baby, which showed an α-globin variant in both. The maternal α2 globin gene sequencing showed heterozygosity for haemoglobin M Boston (α58 His→Tyr).
- 1 January 2013
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 35 (1) , e7-e10
Use of Gemcitabine With Multi-stage Surgical Resection as Successful Second-line Treatment of Metastatic Pancreatoblastoma
Pancreatoblastoma is a rare pediatric pancreatic malignancy. It confers a worse prognosis if there is metastatic or unresectable disease. We report a case of a 12-year-old boy who presented with pancreatoblastoma of the head of the pancreas with multiple intrahepatic metastases. We successfully treated him using aggressive chemotherapy, multi-stage surgery, and gemcitabine chemotherapy, which has not been described as treatment for pancreatoblastoma. Rare childhood malignancies such as pancreatoblastoma require a coordinated, multidisciplinary approach and frequent reassessment of therapeutic interventions. Complete surgical resection is important for cure and may require complex, aggressive, multiple-stage surgical procedures with concurrent or novel chemotherapy.
- 1 January 2013
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 35 (1) , e7-e10
Use of Gemcitabine With Multi-stage Surgical Resection as Successful Second-line Treatment of Metastatic Pancreatoblastoma
Pancreatoblastoma is a rare pediatric pancreatic malignancy. It confers a worse prognosis if there is metastatic or unresectable disease. We report a case of a 12-year-old boy who presented with pancreatoblastoma of the head of the pancreas with multiple intrahepatic metastases. We successfully treated him using aggressive chemotherapy, multi-stage surgery, and gemcitabine chemotherapy, which has not been described as treatment for pancreatoblastoma. Rare childhood malignancies such as pancreatoblastoma require a coordinated, multidisciplinary approach and frequent reassessment of therapeutic interventions. Complete surgical resection is important for cure and may require complex, aggressive, multiple-stage surgical procedures with concurrent or novel chemotherapy.
- 1 January 2012
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 13 (1) , 1-5
Central venous catheter sampling of low molecular heparin levels
The low molecular weight heparin effect in children is monitored using the anti-factor Xa level. Venipuncture is recommended; however, central venous catheter blood sampling is often necessary. Heparin infused through central venous catheters may contaminate central venous catheter blood samples, preventing reliable anti-factor Xa level measurement. Simultaneous anti-factor Xa/partial thromboplastin time measurement with central venous catheter blood sampling may predict anti-factor Xa reliability. To determine the prevalence of heparin contamination as measured by the partial thromboplastin time/anti-factor Xa in central venous catheter blood samples and whether careful sampling could minimize heparin contamination of anti-factor Xa levels from central venous catheter blood sampling. Simultaneous partial thromboplastin time/anti-factor Xa measurements from central venous catheter blood sampling determined the prevalence of heparin contamination of central venous catheter blood samples. In phase II, children receiving low molecular weight heparin had routine central venous catheter blood sampling to measure the peak anti-factor Xa and the simultaneous partial thromboplastin time. Anti-factor Xa levels with a partial thromboplastin time of >40 secs (pair 1) were identified; there was no low molecular weight heparin dose change, and the paired sample was repeated using a careful sampling technique (pair 2). Pairs 1 and 2 were compared to determine the efficiency of the sampling technique in removing heparin from the central venous catheter blood samples. In phase I, 100 children had 485 paired anti-factor Xa/partial thromboplastin time central venous catheter blood samples with 29% ± 4.1% (95% confidence interval 25% to 33%) anti-factor Xa with partial thromboplastin times of >40 secs. In phase II, 43 children had 129 paired anti-factor Xa/partial thromboplastin time samples with partial thromboplastin times of >40 secs. The pair 1 mean partial thromboplastin times/anti-factor Xa levels were 109.8 secs (SD 53.1, range 34.0 to >200 secs) and 1.03 units/mL (SD 0.56, range 0.26-4.2 units/mL). Repeated partial thromboplastin times/anti-factor Xa levels (pair 2) were significantly decreased from those of pair 1 (p < .001) with means of 58.5 secs (SD 21.2, range 22-152 secs) vs. 109.8 secs (SD 53.1, range 34.0 to > 200 secs, p < .001) and 0.63 unit/mL (SD 0.30, range 0.02-1.77 units/mL) vs. 1.03 units/mL (SD 0.56, range 0.26-4.2 units/mL), respectively. Measurement of the partial thromboplastin time performed in combination with that of the anti-factor Xa level can be used to assist health practitioners to identify unfractionated heparin contamination of anti-factor Xa levels drawn from central venous catheters. A careful sampling technique may minimize heparin contamination in central venous catheter blood samples.
- 1 January 2012
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 13 (1) , 1-5
Central venous catheter sampling of low molecular heparin levels
The low molecular weight heparin effect in children is monitored using the anti-factor Xa level. Venipuncture is recommended; however, central venous catheter blood sampling is often necessary. Heparin infused through central venous catheters may contaminate central venous catheter blood samples, preventing reliable anti-factor Xa level measurement. Simultaneous anti-factor Xa/partial thromboplastin time measurement with central venous catheter blood sampling may predict anti-factor Xa reliability. To determine the prevalence of heparin contamination as measured by the partial thromboplastin time/anti-factor Xa in central venous catheter blood samples and whether careful sampling could minimize heparin contamination of anti-factor Xa levels from central venous catheter blood sampling. Simultaneous partial thromboplastin time/anti-factor Xa measurements from central venous catheter blood sampling determined the prevalence of heparin contamination of central venous catheter blood samples. In phase II, children receiving low molecular weight heparin had routine central venous catheter blood sampling to measure the peak anti-factor Xa and the simultaneous partial thromboplastin time. Anti-factor Xa levels with a partial thromboplastin time of >40 secs (pair 1) were identified; there was no low molecular weight heparin dose change, and the paired sample was repeated using a careful sampling technique (pair 2). Pairs 1 and 2 were compared to determine the efficiency of the sampling technique in removing heparin from the central venous catheter blood samples. In phase I, 100 children had 485 paired anti-factor Xa/partial thromboplastin time central venous catheter blood samples with 29% ± 4.1% (95% confidence interval 25% to 33%) anti-factor Xa with partial thromboplastin times of >40 secs. In phase II, 43 children had 129 paired anti-factor Xa/partial thromboplastin time samples with partial thromboplastin times of >40 secs. The pair 1 mean partial thromboplastin times/anti-factor Xa levels were 109.8 secs (SD 53.1, range 34.0 to >200 secs) and 1.03 units/mL (SD 0.56, range 0.26-4.2 units/mL). Repeated partial thromboplastin times/anti-factor Xa levels (pair 2) were significantly decreased from those of pair 1 (p < .001) with means of 58.5 secs (SD 21.2, range 22-152 secs) vs. 109.8 secs (SD 53.1, range 34.0 to > 200 secs, p < .001) and 0.63 unit/mL (SD 0.30, range 0.02-1.77 units/mL) vs. 1.03 units/mL (SD 0.56, range 0.26-4.2 units/mL), respectively. Measurement of the partial thromboplastin time performed in combination with that of the anti-factor Xa level can be used to assist health practitioners to identify unfractionated heparin contamination of anti-factor Xa levels drawn from central venous catheters. A careful sampling technique may minimize heparin contamination in central venous catheter blood samples.
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 33 (3) , e98-e100
Typhlitis in Children With Malignancy
In a case-control study, medical records of all children (below 18 y of age) who were diagnosed with any malignancy between January 1988 and December 2008 were reviewed. Children who developed typhlitis during the course of their malignancy were identified. Age and sex-matched controls who were diagnosed with malignancy during the same time period but did not develop typhlitis were identified (1:4 ratio). The variables that were examined included underlying malignancy, chemotherapy, and final outcome. A total of 410 children (226 males, mean age of 87.29 ± 56.8 mo) with malignancy were recruited. Nine children (0.22%) (4 boys, mean age of 87.56 ± 60.48 mo) developed typhlitis during the course of their disease. In the control group, 36 age and sex-matched children were included (mean age of 87.67 ± 57.91 mo). Children who had Clostridium difficile infection within 8 weeks before developing typhlitis were more likely to develop typhlitis compared with controls (odds ratio 7.99, 95% confidence interval 1.46-43.7, P=0.01). One patient died from typhlitis. Clostridium difficile infection is a risk factor for developing typhlitis in children with cancer. Larger multicenter trials are needed to confirm our conclusions.
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 33 (3) , e98-e100
Typhlitis in Children With Malignancy
In a case-control study, medical records of all children (below 18 y of age) who were diagnosed with any malignancy between January 1988 and December 2008 were reviewed. Children who developed typhlitis during the course of their malignancy were identified. Age and sex-matched controls who were diagnosed with malignancy during the same time period but did not develop typhlitis were identified (1:4 ratio). The variables that were examined included underlying malignancy, chemotherapy, and final outcome. A total of 410 children (226 males, mean age of 87.29 ± 56.8 mo) with malignancy were recruited. Nine children (0.22%) (4 boys, mean age of 87.56 ± 60.48 mo) developed typhlitis during the course of their disease. In the control group, 36 age and sex-matched children were included (mean age of 87.67 ± 57.91 mo). Children who had Clostridium difficile infection within 8 weeks before developing typhlitis were more likely to develop typhlitis compared with controls (odds ratio 7.99, 95% confidence interval 1.46-43.7, P=0.01). One patient died from typhlitis. Clostridium difficile infection is a risk factor for developing typhlitis in children with cancer. Larger multicenter trials are needed to confirm our conclusions.